News & Media

Press release
Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

July – SeptemberSignificant events during the quarter Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension...

Read more
Press release
New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the initial phase II study of MIV-711,...

Read more
Press release
Medivir scales back research costs to focus on clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today plans to reduce activities not critical to its development pipeline of...

Read more
Press release
Medivir to focus on its clinical development and appoints Uli Hacksell as acting CEO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today its plans to concentrate its activities on clinical development. As a...

Read more
Press release
Positive interim data on birinapant in combination with Keytruda®

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced safety and efficacy data following an interim analysis of phase I...

Read more
Press release
Phase I/II clinical study of MIV-818 started in patients with liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and dosed with MIV-818...

Read more
Press release
Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October...

Read more
Press release
Investigator-initiated phase II clinical study of remetinostat started in patients with basal cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed...

Read more
Press release
MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018

April – JuneSignificant events during the quarter Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met...

Read more
Press release
Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202)....

Read more